Health Economics›Gastric cancer›Metastatic or locally advanced disease first-line

Metastatic or locally advanced disease first-line

Gastric cancer · 55 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

FiltersBiomarker

Y-axis

Cost vs Efficacy · 23 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Pembrolizumab monotherapy Variant #01	—	R 286 955	14d	—	~9.1 mo	—	—	1
CapeOx, Pembrolizumab, Trastuzumab Variant #01	ERBB2	R 94 809	21d	10.0 mo	20.0 mo	15	R 1 422 135 PFS proxy	3
Cisplatin and Fluorouracil (CF), Pembrolizumab, Trastuzumab Variant #01	ERBB2	R 93 375	21d	10.0 mo	20.0 mo	15	R 1 400 622 PFS proxy	3
CapeOx and Pembrolizumab Variant #01	—	R 84 371	21d	—	12.9 mo	—	—	1
Capecitabine and Cisplatin (CX) and Pembrolizumab Variant #01	—	R 83 374	21d	—	12.5 mo	—	—	1
Cisplatin and Fluorouracil (CF) and Pembrolizumab Variant #01	—	R 82 937	21d	—	12.7 mo	—	—	2
Capecitabine and Cisplatin (CX), Pertuzumab, Trastuzumab Variant #01	ERBB2	R 54 540	21d	—	18.1 mo	—	—	1
Cisplatin and Fluorouracil (CF), Pertuzumab, Trastuzumab Variant #01	ERBB2	R 54 104	21d	—	18.1 mo	—	—	1
mDCF and Bevacizumab Variant #01	—	R 21 728	14d	—	—	—	—	—
Capecitabine and Cisplatin (CX) and Trastuzumab Variant #01	ERBB2	R 19 082	21d	—	13.8 mo	—	—	2
CapeOx and Trastuzumab Variant #01	ERBB2	R 12 822	21d	8.1 mo	16.8 mo	12	R 153 861 PFS proxy	2
CLF Variant #04	—	R 12 568	42d	3.9 mo	—	3	R 37 705 PFS proxy	—
Fluorouracil, Folinic acid, Mitomycin Variant #01	—	R 11 847	56d	—	—	—	—	—
Cisplatin and Fluorouracil (CF) and Trastuzumab Variant #01	ERBB2	R 11 388	21d	8.1 mo	14.2 mo	12	R 136 651 PFS proxy	4
mFOLFOX6 and Zolbetuximab Variant #01 Partial	—	R 6 438	42d	10.6 mo	18.2 mo	8	R 51 507 PFS proxy	2
OLF Variant #01	—	R 5 928	56d	5.8 mo	—	4	R 23 711 PFS proxy	—
Carboplatin and Paclitaxel (CP) Variant #38	—	R 5 031	21d	~7.4 mo	~27.5 mo	~11	~R 55 338 PFS proxy · indirect	3
ECF Variant #04	—	R 3 931	21d	—	9.2 mo	—	—	—
EOX Variant #01	—	R 3 411	21d	5.5 mo	11.3 mo	8	R 27 284 PFS proxy	3
FAM Variant #01	—	R 3 143	56d	—	—	—	—	—
EOF Variant #01	—	R 3 063	21d	—	~48.0 mo	—	—	1
Fluorouracil and RT Variant #08	—	R 3 059	77d	—	~13.6 mo	—	—	5
FOLFIRI Variant #05	—	R 2 826	14d	~8.2 mo	~16.1 mo	~18	~R 50 875 PFS proxy · indirect	22
mFOLFOX6 and Nivolumab Variant #01 Partial	—	R 2 586	14d	—	14.4 mo	—	—	1
mFOLFOX6 Variant #02	—	R 2 466	14d	7.6 mo	12.2 mo	17	R 41 930 PFS proxy	4
CapeOx and Nivolumab Variant #01 Partial	—	R 2 384	21d	10.7 mo	17.5 mo	16	R 38 147 PFS proxy	5
CapeOx Variant #01	ERBB2	R 2 384	21d	6.5 mo	12.2 mo	10	R 23 842 PFS proxy	15
CapeOx Variant #01	—	R 2 384	21d	6.5 mo	12.2 mo	10	R 23 842 PFS proxy	15
CapeOx and Tislelizumab Variant #01 Partial	—	R 2 384	21d	—	15.0 mo	—	—	1
CapeOx and Zolbetuximab Variant #01 Partial	—	R 2 384	21d	8.2 mo	14.4 mo	12	R 28 611 PFS proxy	2
ECX Variant #01	—	R 2 313	21d	—	10.7 mo	—	—	1
Capecitabine monotherapy Variant #17	—	R 2 219	21d	—	6.9 mo	—	—	2
Docetaxel and S-1 Variant #01 Partial	—	R 1 931	21d	—	12.5 mo	—	—	1
Cisplatin and Fluorouracil (CF) Variant #29	ERBB2	R 1 900	21d	5.0 mo	11.1 mo	8	R 15 201 PFS proxy	7
Cisplatin and Fluorouracil (CF) Variant #29	—	R 1 900	21d	5.0 mo	11.1 mo	8	R 15 201 PFS proxy	7
mDCF Variant #01	—	R 1 634	14d	—	10.2 mo	—	—	1
mFOLFOX6 (L-Leucovorin) Variant #01 Partial	—	R 1 629	14d	—	11.8 mo	—	—	—
FEMTX Variant #01	—	R 1 564	28d	—	—	—	—	—
FULV Variant #01	—	R 1 466	35d	—	7.5 mo	—	—	1
Capecitabine and Cisplatin (CX) Variant #01	ERBB2	R 1 386	21d	5.4 mo	10.6 mo	8	R 11 092 PFS proxy	8
Capecitabine and Cisplatin (CX) Variant #01	—	R 1 386	21d	5.4 mo	10.6 mo	8	R 11 092 PFS proxy	8
UFTM Variant #01 Partial	—	R 1 078	7d	—	—	—	—	—
SOX Variant #01 Partial	—	R 1 075	21d	5.6 mo	—	9	R 9 677 PFS proxy	2
Paclitaxel and S-1 Variant #01 Partial	—	R 971	35d	—	17.7 mo	—	—	1
Fluorouracil monotherapy Variant #16	—	R 858	42d	—	10.8 mo	—	—	2
FULV (L-Leucovorin) Variant #06 Partial	—	R 825	14d	—	6.1 mo	—	—	1
Cisplatin and Fluorouracil (CF) and Tislelizumab Variant #01 Partial	—	R 816	21d	—	15.0 mo	—	—	1
Fluorouracil and Heptaplatin (FH) Variant #01 Partial	—	R 687	28d	—	7.3 mo	—	—	—
FAMTX Variant #01	—	R 545	28d	—	—	—	—	—
Cisplatin and Docetaxel (DC) N/A - secondary systemic drug	—	R 449	21d	~24.0 mo	—	~35	~R 15 722 PFS proxy · indirect	1
Cisplatin and S-1 Variant #01 Partial	—	R 375	28d	5.5 mo	14.1 mo	6	R 2 250 PFS proxy	10
DCF N/A - secondary systemic drug	—	R 228	21d	—	9.2 mo	—	—	1
Irinotecan monotherapy N/A - secondary systemic drug	—	R 47	42d	~2.3 mo	~8.4 mo	~2	~R 95 PFS proxy · indirect	9
Best supportive care Partial	—	—	—	—	~3.7 mo	—	—	4
S-1 monotherapy Variant #01 Partial	—	—	21d	—	10.9 mo	—	—	6

55 of 55 regimens shown